Waldenström Macroglobulinemia: A First-Line Choice Complicated by the Blood Thinner He's Already On
A single patient with newly diagnosed, symptomatic Waldenström macroglobulinemia and pre-existing anticoagulation. The disagreement about his long-term regimen sits alongside, not instead of, an urgent problem that needs its own separate, immediate answer.
H.S., a 71-year-old retired shipping clerk, came to clinic with blurred vision, headache, and a nosebleed that took nearly twenty minutes of direct pressure to stop — symptoms his family recognized as more serious than his usual complaints only because his wife insisted on the visit. Labs showed an IgM above 6,000 mg/dL — roughly the level at which serum viscosity stops being a laboratory abstraction and starts producing exactly the triad he walked in with — and funduscopy found dilated, segmented retinal veins, which is the same finding written on the back of the eye. A marrow biopsy confirmed Waldenström macroglobulinemia with a MYD88 L265P mutation and wild-type CXCR4, the genotype associated with better and faster response to BTK inhibition than CXCR4-mutated disease achieves. He has been on apixaban for atrial fibrillation for three years, which is the fact that turns his most favorable molecular result into his most difficult treatment decision.
Two things are true about H.S. at once, and the team needs to hold both. His hyperviscosity symptoms — the visual changes, the headache, the prolonged nosebleed — are an acute, time-sensitive problem that plasmapheresis treats directly and quickly, regardless of whatever long-term regimen is eventually chosen. Separately, his anticoagulation for atrial fibrillation genuinely complicates that longer-term choice: BTK inhibitors carry a real bleeding risk through their effect on platelet function, and stacking that on top of an existing anticoagulant is a real, drug-class-level interaction to weigh, even though ASPEN, the head-to-head trial of zanubrutinib against ibrutinib in exactly this disease, showed a meaningfully better bleeding and cardiac safety profile than the drug that concern was originally built around.
Inpatient hematology, urgent consultation
For his long-term regimen, zanubrutinib's own head-to-head data against ibrutinib in ASPEN showed a meaningfully lower bleeding and cardiac event rate — that's a direct answer to the anticoagulation concern, not a reason to avoid the drug class on a first-generation agent's toxicity profile.
I'd still flag a real residual concern. Zanubrutinib's improved profile relative to ibrutinib doesn't mean the bleeding-risk mechanism is gone — BTK inhibitors affect platelet function as a class, and stacking any version of that effect on top of a factor Xa inhibitor is a real interaction, even a smaller one. Fixed-duration bendamustine-rituximab sidesteps that combination entirely rather than managing a lower but non-zero version of the same risk.
'Meaningfully lower' isn't the same as 'no longer relevant' — his own anticoagulant status is exactly the situation where even a reduced bleeding-risk signal deserves real weight.
Whatever the two of you decide about his long-term regimen, it doesn't touch what's happening to him right now. His hyperviscosity symptoms — the vision changes, the headache, the nosebleed that took twenty minutes to stop — need plasmapheresis today, regardless of which BTK inhibitor or chemoimmunotherapy combination gets chosen afterward. Neither option acts fast enough to address acute hyperviscosity on its own.
Agreed: urgent plasmapheresis first, followed by fixed-duration bendamustine-rituximab as his long-term regimen rather than a BTK inhibitor, given his anticoagulation.
Left open rather than settled: what should govern for the next patient on anticoagulation who doesn't have as clean a chemoimmunotherapy alternative available? The hematologist-oncologist's reliance on zanubrutinib's comparative safety data was never actually tested against that harder version of the choice — it simply wasn't necessary today, since fixed-duration bendamustine-rituximab was available and uncomplicated for him specifically.